Drug news
FDA postpones PDUFA decision for Duobrii a proposed treatment for psoriasis.- Ortho Dermatologics
Bausch Health Companies Inc.and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced that the FDA will be unable to meet the Prescription Drug User Fee Act (PDUFA) date for the New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, for the topical treatment of plaque psoriasis in adults. The FDA is close to finalizing its review, and a decision is expected shortly.
910 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.